A Study Of PF-04449913 Administered Alone In Select Solid Tumors



Status:Completed
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:9/23/2012
Start Date:May 2011
End Date:December 2012
Contact:Pfizer CT.gov Call Center
Phone:1-800-718-1021

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors


This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway
on select solid tumors.


Inclusion Criteria:

- Histological or cytological diagnosis of advanced/metastatic solid tumor

- Adequate Bone Marrow Function

- Adequate Renal Function

- Adequate Liver Function

Exclusion Criteria:

- Patients with known symptomatic brain metastases requiring steroids

- Current active treatment on another clinical trial

- Major surgery or radiation therapy within 4-weeks of starting study treatment
We found this trial at
3
sites
Pfizer Investigational Site
Boston, Massachusetts 02115
?
mi
from
Boston, MA
Click here to add this to my saved trials
Pfizer Investigational Site
Arvada, Colorado 80005
?
mi
from
Arvada, CO
Click here to add this to my saved trials
Pfizer Investigational Site
Los Angeles, California 90027
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials